Roma, 31 Maggio 2010 - Dal 4 all’8 Giugno a Chicago si terrà il Meeting annuale 2010 dell'American Society of Clinical Oncology (ASCO). L'evento riunisce migliaia di oncologi clinici ed è tra i  più prestigiosi e rilevanti in campo oncologico.
Molti gli specialisti dell’Istituto Nazionale Tumori Regina Elena che sono in partenza per Chicago. Di seguito i lavori che presenteranno:

L. Ciuffreda, et al. Effect of a novel cross-talk mechanism on the RAF/MEK/ERK and PI3K/AKT/mTOR pathways in melanoma: Role of ERK-mediated suppression of PTEN expression. Poster.

Bria E, et al. Prognostic impact of the cytoskeleton regulatory protein hMena in resected node-negative non-small cell lung cancer (NSCLC): A clinical-biological risk stratification model. Poster.

Cuppone F, et al. Magnitude of risks and benefits of the addition of bevacizumab (BEVA) to chemotherapy (CT) for patients (pts) with advanced breast cancer (ABC): Metaregression analysis of randomized trials (RCT). Poster.

Melucci E, et al. Relationship between K-Ras mutational status and EGFR expression evaluated using Allred score in primary and metastatic colorectal cancer. Poster.

Garufi C, et al. CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) plus cetuximab (Cmab) in unselected advanced colorectal cancer (ACC) patients. Poster.

Metro G, et al. Outcome of patients (pts) with brain metastases (BMs) from HER2-positive breast cancer (BC) treated with lapatinib plus capecitabine (LC). Poster.

Vaccaro V, et al. Role of surveillance CT scans in resected PC: Correlation with CA19-9 and symptoms. Poster.

Papaldo P, et al. Individualized administration of capecitabine plus lapatinib in heavily pretreated HER2+ metastatic breast cancer patients: A single-center experience. Poster.

Fabi A, et al. Correlation of efficacy between EGFR gene copy number and lapatinib/capecitabine therapy in HER2-positive metastatic breast cancer. Poster.

Cauchi C, et al. Evaluation of nilotinib (N) in advanced GIST previously treated with imatinib mesylate (IM) and sunitinib (S). Poster.

Programma